<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neuregulin-1 (NRG-1) is a growth factor with potent neuroprotective capacity in <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We recently showed that NRG-1 reduced neuronal <z:hpo ids='HP_0011420'>death</z:hpo> following transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO) by up to 90% with an extended therapeutic window </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we examined the neuroprotective potential of NRG-1 using a permanent MCAO <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (pMCAO) rat model </plain></SENT>
<SENT sid="3" pm="."><plain>NRG-1 reduced infarction in pMCAO by 50% when administered prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We previously demonstrated using gene expression profiling that pMCAO was associated with an exaggerated excitotoxicity response compared to tMCAO </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, we examined whether co-treatment with an inhibitor of excitotoxicity would augment the effect of NRG-1 following pMCAO </plain></SENT>
<SENT sid="6" pm="."><plain>Both NRG-1 and the <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) <z:chebi fb="68" ids="48706">antagonist</z:chebi> MK-801 similarly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size following pMCAO </plain></SENT>
<SENT sid="7" pm="."><plain>However, combination treatment with both NRG-1 and MK-801 resulted in greater neuroprotection than either compound alone, including a 75% reduction in cortical infarction compared to control </plain></SENT>
<SENT sid="8" pm="."><plain>Consistent with these findings, NRG-1 reduced neuronal <z:hpo ids='HP_0011420'>death</z:hpo> using an in vitro <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model and this effect was augmented by MK-801 </plain></SENT>
<SENT sid="9" pm="."><plain>These results demonstrate the efficacy of NRG-1 in pMCAO rat focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings further indicate the potential clinically relevance of NRG-1 alone or as a combination strategy for treating <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>